Phytotherapies

Phytotherapies

Efficacy, Safety, and Regulation
Herausgegeben von Ramzan, Iqbal

• Gebundenes Buch

Produktbeschreibung

Covering fundamentals and new developments in phytotherapy, this book combines pharmaceutical sciences and chemistry with clinical issues.

- Helps readers better understand phytotherapy and learn the fundamentals of and how to analyze phytotherapeutic agents
- Discusses phytotherapy in modern medicine, chemoprevention of disease, and alternatives to western medicines for specific diseases
- Chapters summarizes the uses and applications of phytomedicines, by type like Chinese, Greco-Arab, Indian, European, and Ayurvedic
- Includes international regulatory perspectives and discusses emerging regulations for various established and emerging markets

Produktdetails

• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 672
• Erscheinungstermin: 4. Mai 2015
• Englisch
• Abmessung: 240mm x 161mm x 41mm
• Gewicht: 1182g
• ISBN-13: 9781118268063
• ISBN-10: 1118268067
• Artikelnr.: 41748519

Autorenporträt

Iqbal Ramzan is the Dean of the Faculty of Pharmacy at the University of Sydney, Australia. He is a registered pharmacist and holds a Diploma of the Australian Institute of Company Directors. Dr. Ramzan also served two terms as a Fellow of The University. He is an author/co-author of over 140 publications in pharmacokinetics, pharmacodynamics, drug assays, and drug metabolism. Dr. Ramzan is a member of several professional committees and councils, including the Director of the Council of Pharmacy Schools (Australia and New Zealand). He also serves on the Australian Government's Pharmaceutical SubCommittee of the Advisory Committee on Prescription Medicines.

Inhaltsangabe

List of Contributors xvii Preface xxi 1 Phytotherapies--Past, Present, and
Future 1 Iqbal Ramzan and George Q. Li 1.1 Overview of Phytotherapy 1 1.2
Preclinical Research on Phytotherapies 3 1.3 Clinical Research on
Phytotherapies 6 1.4 Safety of Phytotherapies 8 1.5 Profile of Research in
Complementary Medicine 9 1.6 Summary and Future Directions 12 References 12
2 Quality Control and Quality Assurance of Phytomedicines: Key
Considerations, Methods, and Analytical Challenges 18 Wai?]Ping Yau, Cheong
Hian Goh, and Hwee?]Ling Koh 2.1 Introduction 18 2.2 Key Considerations in
Qc/Qa of Phytomedicines 20 2.3 Methods for Qc/Qa of Phytomedicines 27 2.4
Challenges 37 2.5 Conclusions 40 References 40 3 Preclinical (In Vivo) and
Laboratory (In Vitro) Evidence of Phytomedicine Efficacy 49 Mohi Iqbal
Mohammed Abdul and Tom Hsun?]Wei Huang 3.1 Introduction to Development of
Drugs from Nature 49 3.2 Use of In Vitro and in Vivo Models in Herb Drug
Research: Learning Thus Far 50 3.3 Cardiovascular?] and Stroke?]Related
Diseases: In Vitro and In Vivo Focus 53 3.4 Conclusions 60 References 61 4
Clinical Efficacy Trials with Natural Products and Herbal Medicines 65
Christina L. Nance 4.1 Introduction 65 4.2 Trials in Various Disease States
66 4.3 Natural Product: Green Tea 73 4.4 Egcg Clinical Trials 75 4.5 Human
Clinical Study: Egcg and Hiv?]1 Infection 78 4.6 Conclusion 80 References
80 5 Novel Formulations and Drug Delivery Systems for Phytotherapies 89
Shengpeng Wang, Meiwan Chen, Qi (Tony) Zhou, and Hak?]Kim Chan 5.1
Limitations of Conventional Formulations for Herbal Medicines 89 5.2
Crucial Issues of Developing Novel Delivery Systems for Herbal Medicines 91
5.3 Novel Delivery Systems of Herbal Medicines 93 5.4 Summary 96 References
97 6 Phytotherapies Used by Indigenous Populations 101 Bradley S. Simpson
and Susan J. Semple 6.1 Introduction 101 6.2 Phytotherapies of Indigenous
Australians 103 6.3 Challenges of a Changing Environment 114 6.4
Conclusions 117 References 118 7 Phytotherapies from Traditional Chinese
Medicine 122 Michael Rieder 7.1 Traditional Chinese Medicine 122 7.2 Key
Concepts in Traditional Chinese Medicine 124 7.3 Herbal Medicine and
Traditional Chinese Medicine 126 7.4 Issues in the Development of
Phytotherapy from Traditional Chinese Medicine 130 7.5 Phytotherapies
Developed from Traditional Chinese Medicine 131 7.6 Huang Qin Tang and the
Development of Phy906 134 7.7 Ginseng 136 7.8 Moving Forward 138 References
138 8 Integrating Traditional Greco?]Arab and Islamic Diet and Herbal
Medicines in Research and Clinical Practice 142 Bashar Saad 8.1
Introduction 142 8.2 Food Therapy in Greco?]Arab and Islamic Medicine 147
8.3 Medicinal Plants 157 References 177 9 Evolution of Herbal Medicines in
Europe and its Relationship with Modern Medicine 183 Elizabeth M.
Williamson and Kelvin Chan 9.1 Background 183 9.2 Historical Perspective
184 9.3 European Herbal Medicine: Relationship with Modern Medicine 194 9.4
Summary 194 References 196 10 Chemical Classification and Chemistry of
Phytotherapeutics Constituents 199 Pei H. Cui and Colin C. Duke 10.1
Introduction 199 10.2 Phytochemicals 201 10.3 Other Phytochemicals 215 10.4
Medicinal Effects Relating to Dietary Intake 217 10.5 Natural Products as
Leads for Drug Development 223 10.6 Summary 230 References 230 11
Therapeutic Potential of Ginsenosides in Management of Atherosclerosis 236
Xiao?]Jing Zhang, Huanxing Su, Yi-Tao Wang, and Jian-Bo Wan 11.1
Introduction 236 11.2 Chemical Diversity of Ginsenosides and Distribution
238 11.3 Anti?]Atherosclerotic Effects of Ginsenosides 240 11.4 Underlying
Mechanisms of Ginsenosides Against Atherosclerosis 244 11.5 Conclusions and
Future Perspectives 258 Acknowledgments 258 References 258 12 Phytotherapy
Pharmacophores for Major Cellular Drug Targets 268 Jennifer A. Ong, Paul W.
Groundwater, and David E. Hibbs 12.1 Introduction 268 12.2 What is a
Pharmacophore? 269 12.3 Pharmacophore Models of Cardiovascular Drugs 270
12.4 Pharmacophore Models for Anticancer Drugs 285 12.5 Pharmacophore
Models for Anti?]Inflammatory Drugs 290 12.6 Pharmacophore Models for
Anti?]Infective Drugs 297 12.7 Pharmacophore Models for Neurological Drugs
299 12.8 Pharmacophore Models for Miscellaneous Drugs 305 12.9 Conclusions
309 References 309 13 Use of Kava as a Phytotherapeutic Agent and
Kava?]Related Hepatotoxicity 312 Dong Fu and Iqbal Ramzan 13.1 Introduction
312 13.2 Active Components in Kava 313 13.3 Therapeutic Applications of
Kava 314 13.4 Pharmacology of Kava 314 13.5 Side Effects of Kava 317 13.6
Hepatotoxicity of Kava 318 13.7 Summary and Future Challenges 322
References 323 14 Phytotherapies as New Drug Sources: Gossypol and Curcumin
330 Vivian Wan Yu Liao, Rajeshwar Narlawar, David E. Hibbs, and Paul W.
Groundwater 14.1 Botanical Sources of Gossypol and Curcumin 330 14.2
Stereoisomerism, Tautomerism, and Reactivity 332 14.3 Biological Activity
of Gossypol and its Analogues 337 14.4 Biological Activity of Curcumin and
its Analogues 346 References 360 15 Phytotherapies for the Management of
Obesity and Diabetes 370 Michel Rapinski and Alain Cuerrier 15.1
Introduction 370 15.2 Plants from the North American Pharmacopoeia 372 15.3
Pharmacological Screening: Providing Empirical Evidence for Phytotherapies
379 15.4 Community?]Based Participation: Developing Phytotherapies from
Traditional Knowledge 385 15.5 Conclusions 387 References 387 16
Phytotherapeutics for Cancer Therapy 394 Daniel M.?]Y. Sze, Hao Liu,
Maureen V. Boost, Raimond Wong, and Stephen Sagar 16.1 Introduction 394
16.2 Anticancer Phytotherapeutics With Nk Enhancement 395 16.3 Conclusions
423 References 425 17 Phytomedicines for Fatty Liver Disease and Functional
Gastrointestinal Conditions 429 George Q. Li, Moon?]Sun Kim, Fangming Jin,
and Jun?]Lae Cho 17.1 Introduction 429 17.2 Phytomedicines for Fld 430 17.3
Phytomedicines for Ibs 439 17.4 Phytomedicines for Constipation 444 17.5
Summary and Future Perspectives 448 References 448 18 Phytomedicines for
Inflammatory Conditions 464 Sigrun Chrubasik?]Hausmann 18.1 Traditional
Medicines for Inflammatory Conditions in Europe 464 18.2
Twenty?]First?]Century Update on Paids 465 18.3 Oral Extracts from Salix
Species 465 18.4 Oral Extracts from Harpagophytum procumbens 468 18.5 Oral
Avocado-Soybean Unsaponifiables 469 18.6 Oral Extracts From Tripterygium
wilfordii 473 18.7 Oral Paids Containing Unsaturated Fatty Acids 475 18.8
Other Oral Paids 476 18.9 Topical Paids 477 References 478 19
Phytotherapies for Infectious Diseases: Are These Really Useful? 483 Gail
B. Mahady, Gabrielle Escalante, Pooja Mikkilineni, Laura J. Mahady,
Temitope O. Lawal, and Bolanle A. Adeniyi The History of Medicine 483 19.1
Introduction 484 19.2 Historical Precedent for Natural Products as
Antimicrobial Drugs 486 19.3 Are Phytotherapies Useful for the Treatment of
Infectious Diseases? 487 19.4 Naturally Occurring Compounds that may Reduce
Zoonosis 495 19.5 Synergistic and Additive Effects with Antibiotics 496
19.6 New Emerging Infectious Diseases and those with no Known Treatments
496 19.7 Sars 497 19.8 Reducing Mrsa Carriage 498 19.9 Conclusions 499
References 500 20 Phytomedicines for CNS Disorders: Safety Issues for use
with Antiepileptic Drugs 504 Sophia Yui Kau Fong, Rosina Yau Mok, Qiong
Gao, Yin Cheong Wong, and Zhong Zuo 20.1 Introduction 504 20.2 Methodology
of Systematic Literature Search 506 20.3 Pharmacokinetic Interactions 506
20.4 Pharmacodynamic Interactions 512 20.5 Conclusions 524 References 524
21 Phytotherapies: Drug Interactions in Cancer 536 Andrew J. McLachlan and
Stephen J. Clarke 21.1 Introduction 536 21.2 Use of Herbal and
Complementary Medicines by People Living with Cancer 537 21.3 Mechanisms of
Phytotherapy-Drug Interactions 538 21.4 Selected Examples of Phytotherapy
Medicines that have the Potential to Cause Drug Interactions in Cancer 540
21.5 Future Perspectives: Need for Evidence and Advice to Cancer Patients
and Physicians 546 21.6 Conclusions 547 Acknowledgments 547 Conflict of
Interest 547 References 547 22 Quality Use of Medicines: Considerations in
Phytotherapy 554 Lynn Weekes 22.1 Introduction 554 22.2 Relevance of Qum
for Herbal Medicines 556 22.3 Use of Phytotherapies by Consumers 558 22.4
Consumer Attitudes and Beliefs about Herbal Medicines 559 22.5 Applying the
Qum Framework to Phytotherapies 561 22.6 Building Blocks for Quality Use of
Herbal Medicines 566 22.7 Conclusion 570 References 570 23 Intellectual
Property and Patent Issues with Phytotherapy Products 573 Gint Silins,
Jennifer Tan, and Kelvin Chan 23.1 Introduction 573 23.2 Ip
Rights--Phyto?]Industry 575 23.3 Brief Overview of Patents and the
Patenting Process 578 23.4 Other Types of IP Rights 585 23.5 Patenting
Trends for Phytotherapeutics 587 23.6 Traditional Knowledge and IP Rights
587 Disclaimer 589 References 590 24 International Regulatory Status of
Phytotherapies 593 Ernest V. Linek 24.1 Introduction 593 24.2 Specific
Country Regulations 596 24.3 Future of Phytotherapies: World Health
Organization (Who) 631 Further Reading 634 Index 635